KR20050119673A - 크로메논 인돌 - Google Patents

크로메논 인돌 Download PDF

Info

Publication number
KR20050119673A
KR20050119673A KR1020057018642A KR20057018642A KR20050119673A KR 20050119673 A KR20050119673 A KR 20050119673A KR 1020057018642 A KR1020057018642 A KR 1020057018642A KR 20057018642 A KR20057018642 A KR 20057018642A KR 20050119673 A KR20050119673 A KR 20050119673A
Authority
KR
South Korea
Prior art keywords
formula
compound
radical
butyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057018642A
Other languages
English (en)
Korean (ko)
Inventor
카이 쉬만
헨닝 뵈트허
티모 하인리히
귄터 횔체만
크리스토프 반 암스테르담
게르트 바르토스지크
요아킴 라이브로크
크리스토프 자이프리트
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20050119673A publication Critical patent/KR20050119673A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020057018642A 2003-04-04 2004-03-08 크로메논 인돌 Withdrawn KR20050119673A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10315285A DE10315285A1 (de) 2003-04-04 2003-04-04 Chromenonindole
DE10315285.7 2003-04-04

Publications (1)

Publication Number Publication Date
KR20050119673A true KR20050119673A (ko) 2005-12-21

Family

ID=32981019

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057018642A Withdrawn KR20050119673A (ko) 2003-04-04 2004-03-08 크로메논 인돌

Country Status (18)

Country Link
US (1) US7968551B2 (enExample)
EP (1) EP1611126B1 (enExample)
JP (1) JP4740114B2 (enExample)
KR (1) KR20050119673A (enExample)
CN (1) CN1768056A (enExample)
AR (1) AR043834A1 (enExample)
AT (1) ATE446959T1 (enExample)
AU (1) AU2004226279B2 (enExample)
BR (1) BRPI0408467A (enExample)
CA (1) CA2520892C (enExample)
DE (2) DE10315285A1 (enExample)
DK (1) DK1611126T3 (enExample)
ES (1) ES2335665T3 (enExample)
MX (1) MXPA05010483A (enExample)
PL (2) PL377730A1 (enExample)
PT (1) PT1611126E (enExample)
WO (1) WO2004087692A1 (enExample)
ZA (1) ZA200508922B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
CN104045608B (zh) * 2013-03-11 2016-06-01 天津药物研究院有限公司 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate

Also Published As

Publication number Publication date
DK1611126T3 (da) 2010-01-18
CA2520892C (en) 2012-08-21
EP1611126A1 (de) 2006-01-04
JP4740114B2 (ja) 2011-08-03
WO2004087692A1 (de) 2004-10-14
ATE446959T1 (de) 2009-11-15
PL377730A1 (pl) 2006-02-06
US7968551B2 (en) 2011-06-28
AU2004226279B2 (en) 2010-10-28
PT1611126E (pt) 2010-01-29
BRPI0408467A (pt) 2006-04-04
CN1768056A (zh) 2006-05-03
MXPA05010483A (es) 2005-11-16
ZA200508922B (en) 2007-02-28
JP2006522034A (ja) 2006-09-28
DE10315285A1 (de) 2004-10-14
EP1611126B1 (de) 2009-10-28
CA2520892A1 (en) 2004-10-14
ES2335665T3 (es) 2010-03-31
PL1611126T3 (pl) 2010-02-26
AR043834A1 (es) 2005-08-17
DE502004010296D1 (de) 2009-12-10
US20060258680A1 (en) 2006-11-16
AU2004226279A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
KR100528684B1 (ko) 피페라진 유도체
JP4065034B2 (ja) ピペリジン類およびピペラジン類
KR0154316B1 (ko) 헤테로사이클릭 화합물
KR100361950B1 (ko) 3-인돌릴피페리딘
KR20220141328A (ko) 소분자 sting 길항제
JP2005523310A (ja) 置換インドール
JPH05230059A (ja) ベンゾジオキサン誘導体
JP2022000455A (ja) フラバグリン誘導体
KR20020067589A (ko) 페닐피페라지닐 유도체
KR20050119673A (ko) 크로메논 인돌
WO2011002103A2 (en) A cycloalkane derivative
US12116374B2 (en) Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20060010839A (ko) 세로토닌 재흡수 저해제로서의 인돌 유도체
KR20010013750A (ko) 3-벤질피페리딘
WO2000049017A1 (en) 1-((indoly azacycloalkyl) alkyl)-2,1, 3-benzothiadiazole 2,2-dioxides exhibiting 5-ht2a receptor activity
MXPA05008437A (es) Derivados de benzofurano y el uso de los mismos como antidepresivos y ansioliticos.
TW202321231A (zh) 作為sting拮抗劑之小分子尿素衍生物
CN116478152A (zh) 一种小分子髓细胞增殖抑制剂及其制备方法和应用
KR20010112231A (ko) ５―ｈｔ 재흡수 저해제 및 ５―ｈｔ１ｂ／１ｄ리간드로서의 아미드 및 우레아 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid